Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avantor, Inc. stock logo
AVTR
Avantor
$24.83
-0.2%
$25.10
$16.63
$26.16
$16.87B1.365.70 million shs767,004 shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$280.71
-0.4%
$317.40
$261.59
$431.79
$8.01B0.94204,058 shs36,202 shs
Revvity, Inc. stock logo
PKI
Revvity
$127.73
$113.46
$170.00
$14.57B1.1851,117 shs1.63 million shs
10x Genomics, Inc. stock logo
TXG
10x Genomics
$26.59
-2.4%
$35.81
$24.60
$63.57
$3.17B1.941.55 million shs373,060 shs
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avantor, Inc. stock logo
AVTR
Avantor
+0.61%+3.28%-3.87%+5.16%+24.04%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
+0.76%+1.81%-13.13%-13.30%-26.81%
Revvity, Inc. stock logo
PKI
Revvity
0.00%0.00%0.00%0.00%-11.27%
10x Genomics, Inc. stock logo
TXG
10x Genomics
-0.84%-4.05%-24.83%-40.49%-49.79%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avantor, Inc. stock logo
AVTR
Avantor
4.5742 of 5 stars
2.44.00.03.22.72.53.1
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
4.6234 of 5 stars
3.43.00.04.21.83.31.9
Revvity, Inc. stock logo
PKI
Revvity
4.2718 of 5 stars
3.50.01.73.50.01.74.4
10x Genomics, Inc. stock logo
TXG
10x Genomics
4.36 of 5 stars
4.31.00.04.81.13.30.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avantor, Inc. stock logo
AVTR
Avantor
2.75
Moderate Buy$26.717.59% Upside
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.80
Moderate Buy$468.0066.72% Upside
Revvity, Inc. stock logo
PKI
Revvity
3.00
Buy$115.50∞ Upside
10x Genomics, Inc. stock logo
TXG
10x Genomics
2.58
Moderate Buy$48.5082.40% Upside

Current Analyst Ratings

Latest PKI, TXG, BIO, and AVTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$52.00 ➝ $30.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSell ➝ Sell$30.00 ➝ $26.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$45.00 ➝ $36.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$63.00 ➝ $53.00
5/1/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$57.00 ➝ $32.00
4/29/2024
Avantor, Inc. stock logo
AVTR
Avantor
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$27.00 ➝ $26.00
4/29/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$65.00 ➝ $50.00
4/18/2024
Avantor, Inc. stock logo
AVTR
Avantor
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$23.00 ➝ $25.00
4/18/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $55.00
4/10/2024
Avantor, Inc. stock logo
AVTR
Avantor
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$27.00 ➝ $30.00
4/10/2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $45.00
(Data available from 5/7/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avantor, Inc. stock logo
AVTR
Avantor
$6.97B2.42$1.69 per share14.73$7.77 per share3.20
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.67B3.00$12.14 per share23.12$306.51 per share0.92
Revvity, Inc. stock logo
PKI
Revvity
$3.31B0.00N/A9.88$58.49 per share0.00
10x Genomics, Inc. stock logo
TXG
10x Genomics
$618.73M5.12N/AN/A$6.22 per share4.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avantor, Inc. stock logo
AVTR
Avantor
$321.10M$0.3963.6720.021.503.79%13.01%5.22%7/26/2024 (Estimated)
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
-$637.32M-$21.49N/A24.49N/A-23.86%3.90%2.77%5/7/2024 (Confirmed)
Revvity, Inc. stock logo
PKI
Revvity
$569.18M$7.6815.010.000.5028.94%11.17%5.83%N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$255.10M-$2.23N/AN/AN/A-42.20%-30.85%-24.17%8/1/2024 (Estimated)

Latest PKI, TXG, BIO, and AVTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.04N/A-$2.04N/AN/AN/A  
4/30/2024Q1 2024
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.50-$0.50N/A-$0.50$142.24 million$141.01 million    
4/26/2024Q1 2024
Avantor, Inc. stock logo
AVTR
Avantor
$0.20$0.22+$0.02$0.35$1.68 billion$1.68 billion      
2/15/2024Q4 2023
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.93$3.10+$0.17-$5.94$685.00 million$681.18 million      
2/15/2024Q4 2023
10x Genomics, Inc. stock logo
TXG
10x Genomics
-$0.36-$0.41-$0.05-$0.41$182.73 million$183.98 million    
2/14/202412/31/2023
Avantor, Inc. stock logo
AVTR
Avantor
$0.22$0.25+$0.03$0.35$1.70 billion$1.72 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avantor, Inc. stock logo
AVTR
Avantor
N/AN/AN/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Revvity, Inc. stock logo
PKI
Revvity
$0.28N/AN/A3.65%N/A
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avantor, Inc. stock logo
AVTR
Avantor
0.94
1.61
1.05
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.14
5.83
4.34
Revvity, Inc. stock logo
PKI
Revvity
0.48
2.43
2.15
10x Genomics, Inc. stock logo
TXG
10x Genomics
N/A
5.22
4.45

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Avantor, Inc. stock logo
AVTR
Avantor
95.08%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
Revvity, Inc. stock logo
PKI
Revvity
85.22%
10x Genomics, Inc. stock logo
TXG
10x Genomics
84.68%

Insider Ownership

CompanyInsider Ownership
Avantor, Inc. stock logo
AVTR
Avantor
1.30%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
17.50%
Revvity, Inc. stock logo
PKI
Revvity
0.52%
10x Genomics, Inc. stock logo
TXG
10x Genomics
10.65%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Avantor, Inc. stock logo
AVTR
Avantor
14,500679.27 million670.44 millionOptionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
8,03028.52 million23.53 millionOptionable
Revvity, Inc. stock logo
PKI
Revvity
16,700126.41 million125.76 millionOptionable
10x Genomics, Inc. stock logo
TXG
10x Genomics
1,259119.17 million106.48 millionOptionable

PKI, TXG, BIO, and AVTR Headlines

SourceHeadline
Cathie Woods Latest Buys: 3 Stocks the ARK Invest CEO Cant Get Enough OfCathie Wood's Latest Buys: 3 Stocks the ARK Invest CEO Can't Get Enough Of
investorplace.com - May 6 at 1:04 PM
International Markets and 10x Genomics (TXG): A Deep Dive for InvestorsInternational Markets and 10x Genomics (TXG): A Deep Dive for Investors
zacks.com - May 6 at 10:11 AM
Vestmark Advisory Solutions Inc. Makes New $4.33 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)Vestmark Advisory Solutions Inc. Makes New $4.33 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG)
marketbeat.com - May 4 at 2:39 PM
Research Analysts Issue Forecasts for 10x Genomics, Inc.s Q2 2024 Earnings (NASDAQ:TXG)Research Analysts Issue Forecasts for 10x Genomics, Inc.'s Q2 2024 Earnings (NASDAQ:TXG)
americanbankingnews.com - May 4 at 1:42 AM
Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)Q2 2024 Earnings Estimate for 10x Genomics, Inc. Issued By William Blair (NASDAQ:TXG)
marketbeat.com - May 3 at 7:28 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $36.0010x Genomics (NASDAQ:TXG) PT Lowered to $36.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen10x Genomics (NASDAQ:TXG) Stock Rating Lowered by TD Cowen
americanbankingnews.com - May 3 at 5:14 AM
The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00The Goldman Sachs Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $26.00
americanbankingnews.com - May 3 at 5:14 AM
Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00Stifel Nicolaus Lowers 10x Genomics (NASDAQ:TXG) Price Target to $53.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics (NASDAQ:TXG) PT Lowered to $30.0010x Genomics (NASDAQ:TXG) PT Lowered to $30.00
americanbankingnews.com - May 3 at 5:14 AM
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
prnewswire.com - May 2 at 4:05 PM
TD Cowen Downgrades 10x Genomics (TXG)TD Cowen Downgrades 10x Genomics (TXG)
msn.com - May 2 at 7:37 AM
10x Genomics First Quarter 2024 Earnings: In Line With Expectations10x Genomics First Quarter 2024 Earnings: In Line With Expectations
finance.yahoo.com - May 2 at 7:37 AM
10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results10x Genomics, Inc: 10x Genomics Reports First Quarter 2024 Financial Results
finanznachrichten.de - May 2 at 2:37 AM
10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Sets New 12-Month Low After Analyst Downgrade
americanbankingnews.com - May 2 at 1:18 AM
10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group10x Genomics (NASDAQ:TXG) Given New $30.00 Price Target at UBS Group
marketbeat.com - May 1 at 2:32 PM
10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade10x Genomics (NASDAQ:TXG) Hits New 12-Month Low After Analyst Downgrade
marketbeat.com - May 1 at 11:34 AM
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)Analysts’ Opinions Are Mixed on These Healthcare Stocks: 10x Genomics (TXG), Zoetis (ZTS) and Blueprint Medicines (BPMC)
markets.businessinsider.com - May 1 at 8:41 AM
10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen10x Genomics (NASDAQ:TXG) Downgraded by TD Cowen
marketbeat.com - May 1 at 8:32 AM
Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00Canaccord Genuity Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $50.00
americanbankingnews.com - May 1 at 5:32 AM
10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...10x Genomics Inc (TXG) (Q1 2024) Earnings Call Transcript Highlights: Diverse Revenue Streams ...
finance.yahoo.com - May 1 at 3:41 AM
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
businesswire.com - May 1 at 1:01 AM
10x Genomics: Q1 Earnings Snapshot10x Genomics: Q1 Earnings Snapshot
sfgate.com - April 30 at 10:41 PM
TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024TXG Stock Earnings: 10x Genomics Meets EPS, Misses Revenue for Q1 2024
markets.businessinsider.com - April 30 at 10:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Avantor logo

Avantor

NYSE:AVTR
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Bio-Rad Laboratories logo

Bio-Rad Laboratories

NYSE:BIO
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Revvity logo

Revvity

NYSE:PKI
Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.
10x Genomics logo

10x Genomics

NASDAQ:TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.